What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2, Pre-Registered Trial).

What question did this study set out to answer?

This analysis explores the effectiveness of FLAG therapy in patients with therapy-related CBF-AML compared to de novo CBF-AML.

December 8, 2025BloodOpen Access

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

View Full Paper

Ask AI

Bookmark

Authors

JSJayastu SenapatiThe University of Texas MD Anderson Cancer Center NPNaveen PemmarajuThe University of Texas MD Anderson Cancer Center AQAndres QuesadaThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Exploratory analysis reveals FLAG-based therapy achieves comparable survival in therapy-related and de novo CBF-AML patients, suggesting effective treatment options.

Key Points

This analysis explores the effectiveness of FLAG therapy in patients with therapy-related CBF-AML compared to de novo CBF-AML.
Conducted an exploratory analysis of a Phase 2 clinical trial for FLAG therapy.
Monitored patient responses using quantitative polymerase chain reaction (qPCR) for CBF-specific transcripts.
Evaluated relapse free survival (RFS) and overall survival (OS) from treatment initiation.
Therapy-related CBF-AML patients showed similar RFS and OS rates when treated with FLAG-GO or FLAG-IDA.
Overall survival was comparable between therapy-related CBF-AML and de novo CBF-AML.
Patients treated with FLAG-GO demonstrated a trend towards higher optimal PCR response rates.

Cite This Study

Senapati et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0a3 https://doi.org/10.1182/blood-2025-1724

View Full Paper

Ask AI

Bookmark

Implication

Exploratory analysis reveals FLAG-based therapy achieves comparable survival in therapy-related and de novo CBF-AML patients, suggesting effective treatment options.

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider